Thomas R. Kassberg's most recent trade in Passage Bio Inc was a trade of 143,789 Director Stock Option (right to buy) done . Disclosure was reported to the exchange on May 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Passage Bio Inc | Thomas R. Kassberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 143,789 | 143,789 | - | - | Director Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2025 | 18,443 | 271,266 (0%) | 0% | 0 | Common Stock | ||
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2025 | 6,028 | 265,238 (0%) | 0% | 42.1 | 253,779 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2025 | 508 | 264,730 (0%) | 0% | 42.9 | 21,803 | Common Stock | |
| Passage Bio Inc | Thomas R. Kassberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 174,139 | 174,139 | - | - | Employee Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 11 Mar 2024 | 11,509 | 252,823 (0%) | 0% | 49.9 | 574,644 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2024 | 31,400 | 31,400 | - | - | Stock Option (Right to Buy) | ||
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2024 | 17,800 | 264,660 (0%) | 0% | 0 | Common Stock | ||
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2024 | 1,011 | 264,332 (0%) | 0% | 53.8 | 54,351 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2024 | 957 | 265,617 (0%) | 0% | 0 | Common Stock | ||
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2024 | 274 | 265,343 (0%) | 0% | 53.7 | 14,711 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2023 | 39,400 | 39,400 | - | - | Stock Option (Right to Buy) | ||
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2023 | 22,000 | 252,222 (0%) | 0% | 0 | Common Stock | ||
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2023 | 3,394 | 246,860 (0%) | 0% | 45.6 | 154,936 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2023 | 2,663 | 230,222 (0%) | 0% | 0 | Common Stock | ||
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2023 | 1,968 | 250,254 (0%) | 0% | 45.3 | 89,091 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 11 Mar 2022 | 10,281 | 227,559 (0%) | 0% | 67.0 | 688,930 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2022 | 24,900 | 24,900 | - | - | Stock Option (Right to Buy) | ||
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2022 | 14,000 | 227,840 (0%) | 0% | 0 | Common Stock | ||
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 01 Mar 2022 | 2,374 | 213,840 (0%) | 0% | 66.6 | 158,156 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 14 Oct 2021 | 286 | 216,266 (0%) | 0% | 81.1 | 23,206 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 30 Sep 2021 | 109,734 | 0 | - | - | Stock Option (Right to Buy) | ||
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 30 Sep 2021 | 109,734 | 216,552 (0%) | 0% | 0.3 | 34,018 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Thomas R. Kassberg | CBO & EVP | 06 May 2021 | 363 | 106,818 (0%) | 0% | 113.7 | 41,269 | Common Stock |